Elevated Bone Turnover in an Infantile Patient with Mucolipidosis II; No Association with Hyperparathyroidism

Takanobu Otomo1, 2, Takehisa Yamamoto1, Yasuhiro Fujikawa1, 3, Tsunesuke Shimotsuji1, and Keiichi Ozono2
1 Department of Pediatrics, Minoh City Hospital, Osaka, Japan
2 Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan
3 Present position: Fujikawa Pediatric Clinic

Abstract. This present report concerns an infantile patient with mucolipidosis II, who showed transient cortical bone hyperostosis followed by severe osteopenia. The diagnosis of mucolipidosis II was made based on the leakage of lysosomal enzymes in serum and conditioned media of the patient’s skin fibroblasts, low activity of lysosomal enzymes of the fibroblasts and mutation of c.2086_2089insC (p.L697fs) and c.3565C>T (p.R1189X) in the GNPTAB gene. Bone X-ray analysis demonstrated a periosteal reaction and elevated bone resorption at the age of 2 mo. Bone markers, including alkaline phosphatase, osteocalcin and urine deoxypyridinoline, also indicated a high turnover of bone metabolism; however, no apparent rickets-like changes and no increased levels of PTH were observed. Elevated bone resorption is possibly associated with the leakage of lysosomal enzyme from osteoclasts into bone matrices. Bone formation gradually reduced, and increased bone resorption persisted. This led to severe osteopenia at the age of 6 mo. Characteristic bone findings may contribute to early diagnosis of mucolipidosis II, but their pathogenesis remains to be clarified.

Key words: lysosome, bone formation, bone resorption, parathyroid hormone, osteoclast

Introduction

Lysosomes are organelles involved in protein recycling using various proteolytic enzymes under acidic conditions (1). In addition, lysosomes play significant roles in autophagy and apoptosis (2, 3). The dysfunction of lysosomes leads to many diseases, including mucolipidosis type II alpha/beta (I-cell disease, MIM #252500) and III alpha/beta (pseudo-Hurler polydystrophy, MIM #252600), a genetic lysosomal storage disorder (4, 5). Mucolipidosis II is a rare congenital metabolic disorder caused by deficiency of the uridine diphosphate (UDP)-N-acetylglucosamine:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase (abbreviated to GlcNAc-phosphotransferase). GlcNAc-phosphotransferase consists of an alpha-2/beta-2/gamma-2 hexameric complex. Defect of the enzyme causes failure of the biosynthesis of mannose 6-phosphate, which serves as a recognition signal for targeting acid
proteolytic enzymes to lysosomes (1). Thus, lysosomal enzymes fail to be localized in lysosomes, and their substrates accumulate in the lysosomes of patients. The human GNPTAB gene contains 21 exons and spans 85 kb, encoding the 1256-amino acid peptide consisting of the 928-amino acid N-terminal alpha subunit and the 328-amino acid C-terminal beta subunit (6). The gamma subunit is encoded by a separate gene (GNPTG) (7).

Mucolipidosis II is characterized by severe clinical and radiological features, including a coarse face, retarded psychomotor development and restricted joint mobility (8). Neonates with mucolipidosis II often show small birth weight/length, inguinal hernia, gingival hypertrophy and hip dislocation. Mucolipidosis II is usually more severe than Hurler disease, which has similar phenotypes and a poor prognosis. The most unusual feature of mucolipidosis II is vacuoles in fibroblasts or lymphocytes and inclusion bodies in fibroblasts, causing markedly enlarged lysosomes filled with undigested substrates. High levels of lysosomal enzymes, such as β-hexosaminidase, β-galactosidase, α-mannosidase and arylsulfatase A, are detected in serum or cultured media due to leakage of enzymes from the cell. In addition, these lysosomal enzymes have low activity in the skin fibroblasts of patients.

A characteristic finding on X-ray films of the long bones is the transient increase of periosteal bone formation followed by severe osteopenia (9); however, the causes of the transient increase in periosteal bone formation and osteopenia remain unknown. At an early stage, subperiosteal resorption, rickets-like changes and cloaking may look similar to neonatal hyperparathyroidism. Some cases of mucolipidosis II are associated with neonatal hyperparathyroidism (10). A recent report consisting of 25 individuals with mucolipidosis types II and III indicated normal levels of PTH and PTH-related peptide (PTHrP) associated with normal calcium and phosphorus levels despite the resemblance of the bone phenotype to that of neonatal hyperparathyroidism (11). In that report, the progressive bone and mineral disorder in mucolipidosis II and III is called osteodystrophy of mucolipidosis, and the radiographic features might be caused by the increased sensitivity of skeletal tissue to normal circulating levels of PTH; however, no evidence, such as an elevated level of urinary cAMP, was obtained to support the hypersensitivity to PTH. A few documents on metabolic bone markers in mucolipidosis II have described rapid changes from high bone turnover to low bone formation in neonatal mucolipidosis II and bone histology with findings of osteoclast II and bone histology with findings of osteoclast activation, although they did not clarify the causes of these rapid changes of bone metabolism or the activation of osteoclasts (12).

PTH stimulates bone resorption, increases serum calcium levels and decreases serum phosphate levels, while intermittent administration of PTH promotes bone formation. Severe hyperparathyroidism in neonates or infants is caused genetically by a calcium-sensing receptor defect and is life-threatening due to severe hypercalcemia and multiple rib fractures (13). Maternal hypoparathyroidism or vitamin D deficiency also causes transient neonatal hyperparathyroidism (14). Exposure of the fetus to hypocalcemia is the basis of neonatal hyperparathyroidism. As described above, mucolipidosis II may be an additional cause of neonatal hyperparathyroidism, with impaired transport of calcium through the placenta being a possible reason (10).

In the present paper, we investigated serum and urinary bone markers and PTH levels to elucidate the mechanism of bone changes of neonatal mucolipidosis II.

Case Report

The patient was a boy born small for his gestational age at 40 wk and 2 d of gestation, with Apgar scores of 6 (1 min)/4 (5 min). His birth weight was 2,076 g, and his height was
unclear. There was no parental consanguinity. At birth, he showed micrognathia, overlapping fingers and severe skeletal changes, including thoracic deformity and limited flexion of the joints. Bone X-ray at birth revealed increased periosteal bone formation (periosteal reaction) in the long bones (arrow; Fig. 1A). He also showed severe hemolytic jaundice and needed repeated intubation for deterioration of respiratory status, although these symptoms improved a month after birth. High levels of serum alkaline phosphatase (ALP; over 5,000 U/l) and thinning of total bones continued from birth. At 2 and 6 mo of age, the blood and urine levels of bone markers and serum levels of cytokines were determined (Table 1). At 2 mo of age, he had elevated levels of serum ALP, osteocalcin (BGP) and procollagen type I C-propeptide (PICP), as well as increased urinary excretion of deoxypyridinoline (u-DPD), indicating the presence of high turnover bone disease; however, his renal and liver functions were normal. C-terminal PTH was 0.25 ng/ml (reference: <0.5) at one month old, and the intact PTH level was 59 pg/ml (reference range: 10–60) at 3 mo old, indicating no hyperparathyroidism. At 6 mo of age, the serum level of ALP was decreased by 45% (still above the normal level), and serum BGP and PICP were slightly decreased. On the other hand, u-DPD was almost unchanged. Serum calcium remained in the normal range, and the phosphate levels also returned to normal. The intact PTH level was 25 pg/ml. At 6 mo of age, X-ray films showed severe osteopenia (Fig. 1B). The bone mineral density was low at 1 yr old (L₂-L₄ BMD; 0.226 g/cm²: 39% of that in age-matched normal controls, ref. 15). His lymphocytes showed vacuolation at 2 mo of age. The clinical findings suggested that bone abnormalities were caused by a congenital metabolic disease. At 4 mo old, we diagnosed him with mucolipidosis II by lysosomal enzymatic analysis. He showed approximately half the normal level of β-galactosidase and normal levels of β-hexosaminidase, α-mannosidase and
α-fucosidase in lymphocytes. The plasma levels of these enzymes were highly elevated. These results were confirmed by the lysosomal enzyme activities of skin fibroblasts. He showed extremely low or low levels of β-galactosidase, β-hexosaminidase, α-mannosidase and arylsulfatase A (Table 2). A genetic test was performed and showed mutations of c.2086_2089insC (p.L697fs) and c.3565C>T (p.R1189X) in the GNPTAB gene compound heterozygously (case 2 in ref. 16). He was not given therapy for osteopenia, but did not suffer from any bone fractures. He died at three years old from sepsis following pneumonia. The parents did not consent to an autopsy.

**Discussion**

The X-ray changes of neonatal mucolipidosis II at 2 mo of age are characteristic. The
Elevated Bone Turnover in I-cell Disease

subperiosteal resorption and new bone formation resembled bone abnormalities in neonatal patients with treatment of prostaglandin E1 to maintain the patency of the ductus arteriosus or with neonatal hyperparathyroidism (17). Consistent with the bone X-ray findings, bone markers show increased turnover of bone. In our patient, the serum levels of ALP and BGP, bone formation markers, were elevated, and an increased level of u-DPD, a bone resorption marker, was also observed. Subsequently, the serum ALP levels decreased markedly from 2 to 6 mo of age; however, the level of u-DPD showed only a slight decrease. We also found that increased periosteal bone formation in the long bones disappeared on X-ray films at 6 mo of age, and the bone mineral density was low at 1 yr old. These findings imply that high bone turnover occurs in patients with mucolipidosis II at a few months of age followed by imbalanced high bone resorption, which may lead to low bone density at the age of 6 mo. In other expressions, this metabolic bone disorder shows a transition from the coupling state to uncoupling.

The association of neonatal hyperparathyroidism and mucolipidosis II has been reported. In the reported cases, the radiological features resembled those of intrauterine hyperparathyroidism, and PTH and ALP were elevated (10). Secondary hyperparathyroidism usually resolves spontaneously by 3 or 4 mo of age. Our case seemed to be different from these cases because there was no apparent metaphyseal irregularity and no elevation of PTH, at least after one month old. Indeed, a recent report suggested two radiological patterns in mucolipidosis types II and III, transient neonatal hyperparathyroidism and progressive osteodystrophy (11). The authors suggested the hypothesis that the progress of osteodystrophy is due to the hypersensitivity of bone to PTH because it is similar to chronic osteitis fibrosa cystica without an increase in PTH levels. More neonatal cases of mucolipidosis are necessary to reach a conclusion on the pathogenesis of the bone phenotype; however, it is unlikely that elevated levels of PTH are always associated with bone changes of infantile patients with mucolipidosis II.

Osteoclasts are terminally differentiated multinucleated giant cells specific for bone resorption. Decalcification of bone and degradation of the bone matrix are undertaken at the site of a resorption pit sealed by a sealing zone and encircled by a ruffled border of osteoclasts and bone matrix because it contains acid and proteolytic enzymes, such as cathepsin K, the defect of which causes pycnodysostosis (18). The membrane of the ruffle border has characteristics identical to those of lysosome in osteoclasts, and thus it is called hemilysosome (19). Therefore, it is reasonable to hypothesize that the function of osteoclasts is impaired in mucolipidosis II, as suggested by Robinson et al., while bone resorption is enhanced in mucolipidosis II (12). The increased bone resorption in mucolipidosis may imply that the targeting of enzymes involved in bone resorption is not disturbed in this disorder. Further examination of the targeting of lysosomal enzymes is necessary to elucidate the mechanism by which bone resorption is enhanced in mucolipidosis II. Another possible mechanism by which bone resorption is enhanced in mucolipidosis II is that the excessive release of lysosomal enzymes by osteoclasts leads to increased bone resorption.

In conclusion, a neonatal patient with mucolipidosis II that showed characteristic bone X-ray findings and elevated bone turnover without elevation of the PTH levels was reported in this paper. Characteristic X-ray findings of the bone may contribute to early diagnosis and treatment of mucolipidosis II. Analysis of bone metabolism in mucolipidosis will lead to better understanding of the relationship between bone formation and resorption.

References

1. Braulke T, Bonifacino JS. Sorting of lysosomal
proteins. Biochim Biophys Acta 2009;1793:605–14.
2. Eskelinen EL, Saftig P. Autophagy: a lysosomal degradation pathway with a central role in health and disease. Biochim Biophys Acta 2009;1793:664–73.
3. Otomo T, Higaki K, Nanba E, Ozono K, Sakai N. Inhibition of autophagosome formation restores mitochondrial function in mucolipidosis II and III skin fibroblasts. Mol Genet Metab 2009;98:393–9.
4. Tiede S, Storch S, Lübke T, Henrissat B, Bargal R, Raas-Rothschild A, et al. Mucolipidosis II is caused by mutations in GNPTA encoding the alpha/beta GlcNAc-1-phosphotransferase. Nat Med 2005;11:1109–12.
5. Kudo M, Brem MS, Canfield WM. Mucolipidosis II (I-cell disease) and mucolipidosis IIIA (classical pseudo-hurler polydystrophy) are caused by mutations in the GlcNAc-phosphotransferase alpha/beta-subunits precursor gene. Am J Hum Genet 2006;78:451–63.
6. Kudo M, Bao M, D’Souza A, Ying F, Pan H, Roe BA, et al. The alpha- and beta-subunits of the human UDP-N-acetylglucosamine:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase [corrected] are encoded by a single cDNA. J Biol Chem 2005;280:36141–9.
7. Raas-Rothschild A, Cormier-Daire V, Bao M, Genin E, Salomon R, Brewer K, et al. Molecular basis of variant pseudo-hurler polydystrophy (mucolipidosis IIIC). J Clin Invest 2000;105:673–81.
8. Kornfeld S, Sly WS. I-cell disease and Pseudo-Hurler Polydystrophy: Disorders of lysosomal enzyme phosphorylation and localization. The Metabolic and Molecular Bases of Inherited Disease 2001;138:3469–82.
9. Pazzaglia UE, Beluffi G, Bianchi E, Castello A, Cori A, March A. Study of the bone pathology in early mucolipidosis II (I-cell disease). Eur J Pediatr 1989;148:553–7.
10. Unger S, Paul DA, Nino MC, McKay CP, Miller S, Sochett E, et al. Mucolipidosis II presenting as severe neonatal hyperparathyroidism. Eur J Pediatr 2005;164:236–43.
11. Grace DV, Julie B, Jenny A, Michael F, Janice F, Ravi S, et al. The natural history and osteodystrophy of mucolipidosis types II and III. J Paediatr Child Health 2010;46:316–22.
12. Robinson C, Baker N, Noble J, King A, David G, Silience D, et al. The osteodystrophy of mucolipidosis type III and the effects of intravenous pamidronate treatment. J Inherit Metab Dis 2002;25:681–93.
13. Egbuna OI, Brown EM. Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations. Best Pract Res Clin Rheumatol 2008;22:129–48.
14. Demirel N, Aydin M, Zenciroglu A, Okumus N, Cetinkaya S, Yildiz YT, et al. Hyperparathyroidism secondary to maternal hypoparathyroidism and vitamin D deficiency: an uncommon cause of neonatal respiratory distress. Ann Trop Paediatr 2009;29:149–54.
15. Salle BL, Braillon P, Glorieux FH, Brunet J, Cavero E, Meunier PJ. Lumbar bone mineral content measured by dual energy X-ray absorptiometry in newborns and infants. Acta Paediatr 1992;81:953–8.
16. Otomo T, Muramatsu T, Yorifuji T, Okuyama T, Nakabayashi H, Fukao T, et al. Mucolipidosis II and III alpha/beta: mutation analysis of 40 Japanese patients showed genotype-phenotype correlation. J Hum Genet 2009;54:145–51.
17. Fay-Petersen OM, Johnson WH Jr, Carlo WA, Hedlund GL, Pacifico AD, Blair HC. Prostaglandin E1-induced hyperostosis: clinicopathologic correlations and possible pathogenetic mechanisms. Pediatr Pathol Lab Med 1996;16:489–507.
18. Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996;273:1236–9.
19. Ruivo R, Anne C, Sagné C, Gasnier B. Molecular and cellular basis of lysosomal transmembrane protein dysfunction. Biochim Biophys Acta 2009;1793:636–49.